Long-Term Efficacy and Safety of Renal Denervation for Blood Pressure Reduction

A meta-analysis shows sustained blood pressure reduction after RDN, but with ongoing use of multiple antihypertensive medications.

Renal denervation (RDN) has been developed as a novel treatment for hypertension. Previous studies of RDN, typically using concomitant antihypertensive medications, have found modest blood pressure reduction; however, most studies have been of short duration. In order to understand long-term effects of RDN, investigators pooled mean results from four observational studies with as long as 10 years of follow-up (N=264) and two randomized, sham-controlled trials with 3 years of follow-up (257 patients received RDN, 75 received sham procedure).

RDN was associated with clinically significant blood pressure reductions in both observational and randomized, sham-controlled studies. Using ambulatory blood pressure monitoring, in the four observationa…

Reviewing Author

Karol E. Watson, MD, PhD, FACC

Disclosures

Consultant/Advisory BoardBoehringer Ingelheim; Amgen; Novartis; Lilly; Amarin

Speaker’s BureauBoehringer Ingelheim

Grant/Research SupportNIH

Editorial BoardsCirculation (Associate Editor)